Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214121 · ClinicalTrials.gov registry record · Phase 2
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT02214121 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 46 participants.
The verdict
NCT02214121, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with sickle cell disease
Interventions
- DRUG Ticagrelor Dose 1a + Dose 2a
- DRUG Ticagrelor Dose 1b + Dose 2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-09-11 |
| Est. Completion | 2017-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214121
The ClinicalTrials.gov registry entry for NCT02214121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor Dose 1a + Dose 2a is the first listed.
NCT02214121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214121 about?
NCT02214121 is a clinical study titled "A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease". The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with sickle cell disease
What is the current status of trial NCT02214121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2014-09-11. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02214121?
The interventions under investigation include: Ticagrelor Dose 1a + Dose 2a (DRUG), Ticagrelor Dose 1b + Dose 2b (DRUG).
Who is sponsoring clinical trial NCT02214121?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.